GW Pharmaceuticals Receives Orphan Drug Designation By FDA For Epidiolex® In The Treatment Of Lennox-Gastaut Syndrome

Published: Feb 28, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, Feb. 28, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (AIM:GWP) (Nasdaq:GWPH) ("GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex®, GW's product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant.

Help employers find you! Check out all the jobs and post your resume.

Back to news